Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Related Citations for PubMed (Select 23166415)

1.

Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry.

Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Sim DS, Ahmed S, Hwang SH, Lee MG, Park KH, Kim JH, Ahn Y, Cho MC, Kim CJ, Kim YJ, Park JC, Kang JC; Korea Acute Myocardial Infarction Registry Investigators.

J Korean Med Sci. 2012 Nov;27(11):1339-46. doi: 10.3346/jkms.2012.27.11.1339. Epub 2012 Oct 30.

2.

Comparison of paclitaxel-, sirolimus-, and zotarolimus-eluting stents in patients with acute ST-segment elevation myocardial infarction and metabolic syndrome.

Lee MG, Jeong MH, Ahn Y, Cho JG, Park JC, Kang JC, Chae SC, Hur SH, Hong TJ, Kim YJ, Seong IW, Chae JK, Rhew JY, Chae IH, Cho MC, Bae JH, Rha SW, Kim CJ, Choi D, Jang YS, Yoon J, Chung WS, Seung KB, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Circ J. 2011;75(9):2120-7. Epub 2011 Jul 14.

3.
4.

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.

Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J.

Circulation. 2012 Jun 12;125(23):2873-91. doi: 10.1161/CIRCULATIONAHA.112.097014. Epub 2012 May 14.

5.
6.

Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.

Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators.

Circulation. 2009 Feb 10;119(5):680-6. doi: 10.1161/CIRCULATIONAHA.108.803528. Epub 2009 Jan 26.

7.

Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.

Harjai KJ, Kondareddy S, Pinkosky B, Harjai N, Orshaw P, Boura J.

J Interv Cardiol. 2013 Apr;26(2):153-62. doi: 10.1111/j.1540-8183.2013.12016.x. Epub 2013 Jan 31.

PMID:
23363439
8.

Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.

Kim U, Kim DK, Seol SH, Yang TH, Kim DK, Kim DI, Kim DS, Lee SH, Hong GR, Park JS, Shin DG, Kim YJ, Cho YK, Kim HS, Nam CW, Hur SH, Kim KB.

Clin Cardiol. 2010 Jun;33(6):340-4. doi: 10.1002/clc.20744.

PMID:
20556803
9.

Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.

Kitabata H, Loh JP, Pendyala LK, Badr S, Dvir D, Barbash IM, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Kent KM, Pichard AD, Waksman R.

Am J Cardiol. 2013 Oct 15;112(8):1093-8. doi: 10.1016/j.amjcard.2013.05.054. Epub 2013 Jul 2.

PMID:
23827397
10.

Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.

Jang SJ, Park DW, Kim WJ, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.

Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1106-14. doi: 10.1002/ccd.24603. Epub 2013 Feb 9.

PMID:
22899589
11.

Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.

Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJ; ZEST-AMI Investigators.

Am J Cardiol. 2009 Nov 15;104(10):1370-6. doi: 10.1016/j.amjcard.2009.06.059. Epub 2009 Sep 26.

PMID:
19892052
12.

Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.

Markovic S, Paliskyte R, Rottbauer W, Wöhrle J.

Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):307-10. doi: 10.1016/j.carrev.2012.09.003.

PMID:
23164475
13.

Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.

Damman P, Abdel-Wahab M, Möllmann H, Richardt G, Chevalier B, Barragan P, Tijssen JG, Underwood P, Hamm CW.

J Invasive Cardiol. 2012 Oct;24(10):495-502.

14.

Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction.

Park KW, Lim WH, Kim JH, Kang SH, Seo JW, Song YB, Hahn JY, Lee HY, Kang HJ, Cho YS, Youn TJ, Koo BK, Choi SH, Chae IH, Gwon HC, Choi DJ, Kim HS.

Int J Cardiol. 2013 Jun 5;166(1):118-25. doi: 10.1016/j.ijcard.2011.10.012. Epub 2011 Nov 5.

PMID:
22062892
15.

Long-term outcomes comparison of different types of DES in elderly patients from a real-world experience.

Sanfilippo A, Cumbo M, Caggegi AM, Monaco S, Bucalo R, Ruperto C, Tamburino C, Ussia GP, Galassi AR, Capranzano P, Capodanno D, Tamburino C.

J Invasive Cardiol. 2009 Jul;21(7):330-3.

16.

The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.

Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Schenkeveld L, van Domburg R, Serruys PW; Interventional Cardiologists of the Thoraxcenter (2000 to 2007).

J Am Coll Cardiol. 2009 Jul 14;54(3):269-76. doi: 10.1016/j.jacc.2009.05.016.

18.

Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.

Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ; KAMIR Investigators.

JACC Cardiovasc Interv. 2012 Sep;5(9):936-45. doi: 10.1016/j.jcin.2012.05.009.

19.

Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).

Hanna NN, Gaglia MA Jr, Torguson R, Ben-Dor I, Gonzalez MA, Collins SD, Syed AI, Maluenda G, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R.

Am J Cardiol. 2010 Aug 15;106(4):504-10. doi: 10.1016/j.amjcard.2010.04.001.

PMID:
20691308
20.

Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Choi CU, Rha SW, Chen KY, Li YJ, Poddar KL, Jin Z, Minami Y, Suh SY, Na JO, Lim HE, Kim JW, Kim EJ, Park CG, Seo HS, Oh DJ.

Circ J. 2009 Dec;73(12):2229-35. Epub 2009 Sep 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk